AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34840031
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment + AFO-202 beta glucan (n=8)
Trial: 34840031
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment + combination of AFO-202 and N-163 beta glucans (n=8)
Trial: 34840031
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (control group, n=8)
Trial: 32831151
Drug: Shenfu injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu injection (100 ml, twice a day for 7 days)
Trial: 32831151
Drug: Saline (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (identical volume, twice a day for 7 days)
Trial: 32831151
Drug: Shenfu injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu injection
Trial: 34929690
Drug: Goal-directed care
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed care bundle (early intensive blood pressure lowering, glycaemic control, treatment of pyrexia, and reversal of anticoagulation)
Trial: 36202236
Drug: COVID-19 vaccine
RxNorm normalized name: COVID-19 VACCINE
DrugBank: VidPrevtyn Beta (DB16427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 vaccine message group
Trial: 34459398
Drug: Insulin‐like growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin‐like growth factor‐binding protein 2 (AD APOE‐ PRS)
Trial: 33039390
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for pelvic organ prolapse
Trial: 34028358
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (14 weeks, therapist-guided)
Trial: 32338459
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg generic dabigatran etexilate capsule (test drug)
Trial: 32338459
Drug: Commercial dabigatran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial dabigatran etexilate capsule (Pradaxa® , reference drug)
Trial: 34820856
Drug: >20 cc/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: >20 cc/kg volume of leukoreduced RBC transfusions
Trial: 38212068
Drug: Selective Internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective Internal Radiation Therapy (SIRT)
Trial: 34848312
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion (1 µg.kg‐1 loading, 0.6 µg.kg‐1.h‐1 infusion)
Trial: 34848312
Drug: Lignocaine-dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine-dexmedetomidine infusion (1.5 mg.kg‐1 loading, 2 mg.kg‐1.h‐1 infusion and 1 µg.kg‐1 loading, 0.5 µg.kg‐1.h‐1 infusion)
Trial: 34848312
Drug: Lignocaine infusion
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine infusion (1.5 mg.kg‐1 loading, 2 mg.kg‐1.h‐1 infusion)
Trial: 34848312
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (10 mL loading, 1 mL.kg‐1.h‐1 infusion)
Trial: 33171597
Drug: Korean Red
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean Red Ginseng (2 g once daily)
Trial: 33171597
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 g once daily)
Trial: 34086485
Drug: Technology-facilitated self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technology-facilitated self-management support with weekly automated interactive voice response telephone calls for 12 months
Trial: 36350359
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D intake from supplements
Trial: 34001024
Drug: Ambient bright
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambient bright light treatment (1000 lx, 6000 K from 10:00 to 15:00)
Trial: 32787848
Drug: Vaginally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginally administered conjugated estrogens tablet (0.625 mg, daily for 3 weeks then twice weekly for 9 weeks)
Trial: 33735517
Drug: Biofeedback relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback relaxation (BR) during LA administration
Trial: 33735517
Drug: Audio-visual (AV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Audio-visual (AV) distraction during LA administration
Trial: 32115032
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of NAM (50 mg/kg)
Trial: 32115032
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of NAM (100 mg/kg)
Trial: 32115032
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of BA (500 mg/kg)
Trial: 32115032
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of BA (1,000 mg/kg)
Trial: 32115032
Drug: Compound supplement
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound supplement (50 mg/kg NAM + 500 mg/kg BA)
Trial: 34070910
Drug: Oral native
RxNorm normalized name: Castanea sative leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral native vitamin D3 at a dose of 2000 IU once a day for 12 months
Trial: 34555481
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose secukinumab (75/75/150 mg)
Trial: 34555481
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose secukinumab (75/150/300 mg)
Trial: 33762414
Drug: Recombinant adjuvanted
RxNorm normalized name: zoster vaccine, recombinant adjuvanted intramuscular powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant adjuvanted vaccine (RZV)
Trial: 33762414
Drug: Live-attenuated vaccine
RxNorm normalized name: Chikungunya vaccine (live, attenuated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live-attenuated vaccine (ZVL)
Trial: 32706681
Drug: Lottery incentive
RxNorm normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [BEACH DREAM GLITTERY SUNSCREEN SPF 50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lottery incentive (US $50 weekly lottery drawing)
Trial: 32401873
Drug: Rothbaum cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rothbaum cognitive behavioral therapy protocol (individual treatment)
Trial: 32401873
Drug: Rothbaum cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rothbaum cognitive behavioral therapy protocol (group treatment)
Trial: 32401873
Drug: Rothbaum cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rothbaum cognitive behavioral therapy protocol (both individual and group formats)
Trial: 35346332
Drug: Levetiracetam plus
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam plus temozolomide chemotherapy for 34 weeks
Trial: 35346332
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets plus temozolomide for 34 weeks
Trial: 32585438
Drug: In-bed cycling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-bed cycling (30 min daily) in addition to usual-care physiotherapy
Trial: 33028675
Drug: Baricitinib (once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib (once-daily oral dosing)
Trial: 34773803
Drug: Berberine (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine (900 mg per day)
Trial: 32599716
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (0.0055 g·kg−1 post training set)
Trial: 32599716
Drug: Placebo (0.0055
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.0055 g·kg−1 post training set)
Trial: 35157829
Drug: Abemaciclib 200
RxNorm normalized name: abemaciclib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib 200 mg orally twice daily for 24 weeks
Trial: 32972289
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg oral clarithromycin twice a day
Trial: 32972289
Drug: 20 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg/day systematic glucantime
Trial: 32691120
Drug: Tramadol 100
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 100 mg orally
Trial: 32691120
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg orally
Trial: 34326131
Drug: GEN-1 (IL12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEN-1 (IL12 plasmid) administered in eight weekly intraperitoneal infusions starting at cycle 1 week 2 in combination with three 21-day cycles of NACT carboplatin AUC 6 and weekly paclitaxel 80 mg/m2
Trial: 34326131
Drug: NACT carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NACT carboplatin AUC 6 and weekly paclitaxel 80 mg/m2
Trial: 34939363
Drug: Jujube syrup
RxNorm normalized name: JUJUBE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jujube syrup (10 cc per day)
Trial: 34939363
Drug: Placebo syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo syrup (10 cc per day)
Trial: 35451020
Drug: 25% dextrose
RxNorm normalized name: Delflex with 4.25% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% dextrose (0.5 mL orally)
Trial: 35451020
Drug: 24% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24% sucrose (0.5 mL orally)
Trial: 33667495
Drug: Nasal nocturnal
RxNorm normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nasal nocturnal oxygen supplementation (NOS) at 2 L/min
Trial: 32044621
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 50 mg plus Hyoscine‐N‐Butylbromide 10 mg
Trial: 35293520
Drug: CBD (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD (300 mg)
Trial: 32186246
Drug: Multicap (capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicap (capsule containing aspirin, atenolol, ramipril, and simvastatin)
Trial: 32186246
Drug: Control (separate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (separate pills for each drug)
Trial: 33251914
Drug: Early-initiated oral
RxNorm normalized name: valbenazine
DrugBank: Valbenazine (DB11915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early-initiated oral anticoagulation (OAC) prescribed within 30 days after surgery to 1,770 patients (24.0% of those with POAF)
Trial: 33640067
Drug: Screening plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening plus Eave Tubes (10% wettable powder formulation of β‐cyfluthrin)
Trial: 36038881
Drug: Daily Caloric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Caloric Restriction (DCR)
Trial: 35404015
Drug: DS-8895a at
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-8895a at 1 mg/kg (Cohort 1)
Trial: 35404015
Drug: DS-8895a at
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-8895a at 3 mg/kg (Cohort 2)
Trial: 36364963
Drug: Diet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet therapy (protein 1.2−1.5 g/kg) and probiotics for two months
Trial: 36364963
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without diet therapy and probiotics
Trial: 33076888
Drug: Corticosteroid trigger
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid trigger point injection (TPI)
Trial: 32965160
Drug: Sinusoidal linear
RxNorm normalized name: Aspalathus linearis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinusoidal linear accelerations ranging from 0.03 Hz at 0.5 mG to 0.2 Hz at 5 mG
Trial: 33350787
Drug: ASF (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASF (a Compound of Traditional Chinese Medicine)
Trial: 34182873
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone (200 mg daily from 16 to 33 weeks of gestation)
Trial: 35358063
Drug: Gabapentin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (50 mg/kg)
Trial: 33218742
Drug: Naltrexone +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone + Bupropion (NB) 50/300 mg
Trial: 35556946
Drug: MitoQ (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MitoQ (100 - 160 mg based on body mass)
Trial: 33639922
Drug: Yoga intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga intervention (tailored group classes twice a week for 16 weeks)
Trial: 33123119
Drug: Pandemic adjuvanted
RxNorm normalized name: pangamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pandemic adjuvanted vaccine
Trial: 33123119
Drug: One vaccination
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One vaccination dose
Trial: 33123119
Drug: Two vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two vaccination doses
Trial: 33123119
Drug: Pre-existing antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-existing antibodies before vaccination
Trial: 33123119
Drug: De novo
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De novo anti-HLA antibodies
Trial: 35073492
Drug: Tinnitus Retraining
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinnitus Retraining Therapy (TRT; counseling and conventional sound generators)
Trial: 35073492
Drug: Partial Tinnitus
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial Tinnitus Retraining Therapy (pTRT; counseling and placebo sound generators)
Trial: 34121308
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (Lantus®)
Trial: 32179562
Drug: Montmorency tart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montmorency tart cherry juice daily for a 12-month period
Trial: 32403118
Drug: POMA 320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POMA 320 mg/d
Trial: 32403118
Drug: POMA 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POMA 80 mg/d
Trial: 32403118
Drug: TS-134 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TS-134 20 mg/d
Trial: 32403118
Drug: TS-134 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TS-134 60 mg/d
Trial: 34307079
Drug: PROB 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PROB 3 (3 ml of probiotic)
Trial: 34307079
Drug: PROB 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PROB 2 (2 ml of probiotic)
Trial: 32217809
Drug: Pasireotide 40
RxNorm normalized name: pasireotide 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 40 or 60 mg
Trial: 32217809
Drug: Pasireotide 60
RxNorm normalized name: pasireotide 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 60 mg (for uncontrolled patients)
Trial: 32185729
Drug: VisuEvo® (self-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VisuEvo® (self-administered three times daily for the whole study duration)
Trial: 32185729
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no tear substitute administration)
Trial: 33091202
Drug: 1.8% liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8% liposomal TA twice daily
Trial: 33091202
Drug: Microneedling with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedling with 5% TA solution weekly
Trial: 34678908
Drug: Shenfu injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu injection (SFI) + azithromycin + 100 mL 5% glucose injection
Trial: 34678908
Drug: azithromycin +
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin + 150 mL 5% glucose injection
Trial: 32747522
Drug: Fremanezumab quarterly
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fremanezumab quarterly or monthly
Trial: 35865278
Drug: Raising Our
RxNorm normalized name: cetirizine
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raising Our Spirits Together (ROST), a technology‐assisted cognitive behavioral therapy (T‐CBT) for depression, delivered virtually in a small group format across 8 weekly sessions via videoconferencing software.
Trial: 35276897
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of Medium-Chain Triglycerides (MCTs) daily for 2 weeks
Trial: 33373464
Drug: Ibuprofen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (600 mg 3 times daily for 3 days, then placebo for 4 days)
Trial: 33373464
Drug: Ibuprofen (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (3 times daily for 7 days)
Trial: 32831133
Drug: Adjunct therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunct therapeutic plasma exchange (TPE)
Trial: 32567124
Drug: Oral PALO
RxNorm normalized name: palo verde pollen extract
DrugBank: Parkinsonia florida pollen (DB11006)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PALO 0.50 mg
Trial: 32567124
Drug: IV PALO
RxNorm normalized name: palo verde pollen extract
DrugBank: Parkinsonia florida pollen (DB11006)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV PALO 0.25 mg
Trial: 36109791
Drug: Carrageenan nasal
RxNorm normalized name: Carrageenan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrageenan nasal and throat spray (1.2 mg iota-carrageenan, 0.4 mg kappa-carrageenan, 0.5% sodium chloride) applied daily for 8 weeks
Trial: 36109791
Drug: Placebo (0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.5% sodium chloride) applied daily for 8 weeks
Trial: 36109791
Drug: Carrageenan nasal
RxNorm normalized name: Carrageenan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrageenan nasal and throat spray
Trial: 33069664
Drug: Caffeine dose
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine dose > 1.3 mg/kg
Trial: 32213484
Drug: Self-managed, computerised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-managed, computerised speech and language therapy
Trial: 35851035
Drug: nHF 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nHF 6 L/min
Trial: 34969712
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 for 6 cycles (Arm A)
Trial: 35047809
Drug: Non-operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative treatment (6-week cast immobilization)
Trial: 36219303
Drug: Self-monitoring plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-monitoring plus self-titration of antihypertensive medication
Trial: 32401557
Drug: individual child-focused
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: individual child-focused cognitive behavioral therapy (CBT)
Trial: 36450540
Drug: Agent balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agent balloon coated with a low-dose formulation of paclitaxel (2 μg/mm2)
Trial: 36450540
Drug: SeQuent Please
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SeQuent Please paclitaxel-coated balloon (3 μg/mm2)
Trial: 36450540
Drug: Agent in
RxNorm normalized name: Plant agent insecticide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agent in ISR substudy
Trial: 34854315
Drug: Appropriate ICD
RxNorm normalized name: ICDMT
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Appropriate ICD therapy
Trial: 33162198
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group with identifiable victim message
Trial: 33162198
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group with exponential transmission message
Trial: 36174257
Drug: Multi-function swing
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multi-function swing suspension training program (MFSST)
Trial: 32325419
Drug: Tecemotide (L-BLP25)
RxNorm normalized name: L
DrugBank: Tecemotide (DB12568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tecemotide (L-BLP25) added to standard-of-care treatment
Trial: 32325419
Drug: Standard-of-care treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care treatment alone
Trial: 33909194
Drug: Monthly pharmaceutical
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly pharmaceutical care follow-up for 6 months
Trial: 33947355
Drug: Prednisolone 1
RxNorm normalized name: prednisolone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 1 mg/kg/day (maximum 50 mg/day) for 10 days